Molecular signature of response to pazopanib salvage therapy for urothelial carcinoma Journal Article

   

Authors:	Pinciroli, P.; Won, H.; Iyer, G.; Canevari, S.; Colecchia, M.; Giannatempo, P.; Raggi, D.; Pierotti, M. A.; De Braud, F. G.; Solit, D. B.; Rosenberg, J. E.; Berger, M. F.; Necchi, A.
Article Title:	Molecular signature of response to pazopanib salvage therapy for urothelial carcinoma
Keywords:	cancer chemotherapy; clinical article; controlled study; treatment response; unclassified drug; somatic mutation; salvage therapy; cancer patient; multiple cycle treatment; epidermal growth factor receptor 2; genetic variability; angiogenesis; fibroblast growth factor receptor 3; tumor marker; human genome; mammalian target of rapamycin; pazopanib; dna sequence; polo like kinase 2; drug treatment failure; transitional cell carcinoma; chromatin assembly and disassembly; estrone; molecularly targeted therapy; copy number variation; phase 2 clinical trial (topic); peptides and proteins; germline mutation; clinical benefit; advanced disease; indel mutation; transcription factor nrf2; next generation sequencing; cancer prognosis; next-generation sequencing; phosphatidylinositol 4,5 bisphosphate 3 kinase; phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha; human; article; lysine k specific demethylase 6a; stromal antigen 2; swi snf related matrix associated actin dependent regulator of chromatin subfamily a member 4
Journal Title:	Clinical Genitourinary Cancer
Volume:	14
Issue:	1
ISSN:	1558-7673
Publisher:	Elsevier Inc.
Date Published:	2016-02-01
Start Page:	e81
End Page:	e90
Language:	English
DOI:	10.1016/j.clgc.2015.07.017
PROVIDER:	scopus
PUBMED:	26371421
PMCID:	PMC5003615
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84952872750&partnerID=40&md5=d682d2dbc5ff858c41a478c5113dd464
Notes:	Article -- Export Date: 3 February 2016 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/87778